<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973944</url>
  </required_header>
  <id_info>
    <org_study_id>NL60764.068.17</org_study_id>
    <nct_id>NCT03973944</nct_id>
  </id_info>
  <brief_title>ReachPR Trial Resynchronization Therapy in Heart Failure Patients With Prolonged PR Interval</brief_title>
  <official_title>Restoration of Atrioventricular Coupling by Cardiac Resynchronization Therapy in Heart Failure Patients With Prolonged PR Interval</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Prolongation of the electrocardiographic PR interval (PR interval &gt; 200ms; also&#xD;
      known as first-degree atrioventricular block) is frequently encountered in clinical practice&#xD;
      and is generally considered as a benign sign. However, there is increasing evidence that a&#xD;
      prolonged PR interval results in poor hemodynamic performance with elevated left ventricular&#xD;
      (LV) end-diastolic pressures evidenced by diastolic mitral regurgitation. Previous studies&#xD;
      have also associated a prolonged PR interval with a substantially increased risk of future&#xD;
      atrial fibrillation (AF) and pacemaker-implantation, and increased risk of heart failure (HF)&#xD;
      hospitalization and death. These risks stress the importance of proper atrioventricular (AV)&#xD;
      coupling. Shortening of the PR interval may be especially important in heart failure patients&#xD;
      and can be obtained by atrioventricular pacing. A possible adverse effect of ventricular&#xD;
      pacing is that it results in ventricular dyssynchrony which may lead to worsening cardiac&#xD;
      function. This effect may be prevented by applying atrio-biventricular pacing. Data from&#xD;
      several previous (sub)studies have suggested this.&#xD;
&#xD;
      Objective: The purpose of this study is to investigate the acute hemodynamic effects of&#xD;
      restoration of atrioventricular coupling by atrio-biventricular pacing in patients with heart&#xD;
      failure and prolonged PR interval.&#xD;
&#xD;
      Study design: This study will be a multi-center, exploratory, prospective interventional,&#xD;
      nonrandomized acute hemodynamic study, using patients as their own controls.&#xD;
&#xD;
      Study population: The study will enroll 26 patients with symptomatic heart failure, reduced&#xD;
      left ventricular ejection fraction (LVEF) (&lt; 35%) and prolonged PR interval (&gt;230ms), but&#xD;
      without seriously prolonged QRS duration (&lt;150ms) or left bundle branch block (LBBB) QRS&#xD;
      pattern, who are candidates for an implantable cardioverter defibrillator (ICD) device&#xD;
      according to current guidelines.&#xD;
&#xD;
      Main study parameters/endpoints: The main study parameter will be the acute hemodynamic&#xD;
      change in left ventricular stroke work (SW) during atrioventricular optimization by&#xD;
      atrio-biventricular pacing. Secondary parameters will be the acute hemodynamic changes in&#xD;
      left ventricular dP/dt|max and left ventricular stroke volume (SV) by invasive measurements&#xD;
      and in left ventricular stroke volume, diastolic mitral regurgitation and left ventricular&#xD;
      diastolic filling time by echocardiography during atrioventricular optimization by&#xD;
      atrio-biventricular pacing.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The patients are candidates for an ICD device in whom cardiac resynchronization&#xD;
      therapy (CRT) can be considered according to current guidelines. Patients in the present&#xD;
      study will receive a CRT-defibrillator (CRT-D). The risk and/or complications of the CRT-D&#xD;
      implantation are not additional for this study. After the implantation, acute invasive&#xD;
      hemodynamic measurements will be performed with a pressure-volume catheter, which is inserted&#xD;
      via the femoral artery and adds approximately 30 minutes to the standard procedure. An extra&#xD;
      radiation dose of approximately 50mGy is needed to place the pressure volume catheter in the&#xD;
      LV cavity. Local vascular complications of femoral artery puncture like bleeding or damage to&#xD;
      the vessel wall may occur but are rare. The non-invasive echocardiographic protocol one to&#xD;
      two weeks after implantation will add approximately 45 minutes to the routine outpatient&#xD;
      clinic visit. The patients do not have to visit the clinic outside the routine outpatient&#xD;
      clinic visits before and after a CRT-D implantation. The patients will have the potential&#xD;
      direct benefit from the procedure, by finding the patient's specific optimal&#xD;
      (atrioventricular) settings and thereby reducing above described risks of a prolonged PR&#xD;
      interval. In case of a worse hemodynamic performance due to the procedure, the CRT-D will be&#xD;
      programmed to back up pacing and there is no harm for the patient outside the above&#xD;
      subscribed extra measurements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Anticipated">December 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular stroke work</measure>
    <time_frame>Acute measurements (during the cardiac resynchronization therapy device-implantation; duration: approximately 1 hours)</time_frame>
    <description>The acute hemodynamic changes in left ventricular stroke work (SW) during atrioventricular optimization by atrio-biventricular pacing.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Atrioventricular Dyssynchrony</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cardiac resynchronization therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>AV coupling by atrio-biventricular pacing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy</intervention_name>
    <description>Atrio-biventricular pacing to shorten the prolonged PR interval</description>
    <arm_group_label>Cardiac resynchronization therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication for an ICD device according to current guidelines (24);&#xD;
&#xD;
          -  Stable prolonged PR interval &gt;230ms;&#xD;
&#xD;
          -  LVEF (&lt; 35%);&#xD;
&#xD;
          -  New York Heart Association (NYHA) functional class II, III or ambulant IV;&#xD;
&#xD;
          -  Stable sinus rhythm (no documented AF-episodes during the last 4 weeks prior to&#xD;
             inclusion);&#xD;
&#xD;
          -  Optimal HF (oral) medication, and on a stable medication scheme at least 1 month prior&#xD;
             to enrolment; (2)&#xD;
&#xD;
          -  Age â‰¥ 18 years and &lt; 80 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Already implanted with an CRT device;&#xD;
&#xD;
          -  Resting Heart rate &gt;90 bpm;&#xD;
&#xD;
          -  Left bundle branch block (LBBB) QRS morphology;&#xD;
&#xD;
          -  QRS duration &gt;150ms&#xD;
&#xD;
          -  Recent myocardial infarction (within 40 days prior to enrolment);&#xD;
&#xD;
          -  Recent coronary artery bypass graft or valve surgery (within 90 days prior to&#xD;
             enrolment);&#xD;
&#xD;
          -  Chronic renal failure requiring dialysis;&#xD;
&#xD;
          -  Presence of frequent ventricular premature beats (VPB) (&gt;5% on 24h rhythm monitoring&#xD;
             or &gt;2 VPB's on ECG at enrolment);&#xD;
&#xD;
          -  Moderate to severe aortic valve stenosis (AVA&lt;1,5) or a mechanical aortic valve;&#xD;
&#xD;
          -  No femoral arterial access;&#xD;
&#xD;
          -  Second or third degree AV block;&#xD;
&#xD;
          -  Life expectancy &lt; 1 year;&#xD;
&#xD;
          -  Enrolment in one or more ongoing studies that could influence the results of this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Vernooy, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Floor Salden, MD</last_name>
    <phone>031 43 38 84520</phone>
    <email>f.salden@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Floor Salden, MD</last_name>
      <phone>+31-43-3884520</phone>
      <email>floor.salden@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Frits Prinzen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Floor Salden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Vernooy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

